Semaglutide: an evidence-first deep dive

This quiz is separate from the lesson so you can finish learning first, then test what you retained.

Lesson checkpoint

Semaglutide: an evidence-first deep dive checkpoint

This checkpoint tests the lesson you just completed. Passing marks it complete and unlocks the next course step.

Get every question correct to pass.

1. What makes semaglutide a useful example of a mature evidence story?

Its mechanism is enough by itselfLarge randomized human trials directly measured relevant outcomesIt has the most online discussionEvery GLP-1 medicine has identical effects

2. What did STEP 1 directly measure as a primary outcome?

Body-weight change in adults with overweight or obesityHair growthTendon strengthOnly a laboratory biomarker

3. Why is SELECT important as a separate study?

It tested cardiovascular events directly rather than assuming weight loss guaranteed themIt proved every semaglutide product is interchangeableIt was an animal studyIt only measured receptor binding

4. Which statement best reflects evidence-first interpretation of semaglutide?

Strong evidence means every formulation and population can be treated the sameStrong evidence supports specific conclusions inside the studied product, population and outcome contextApproved status makes adverse effects irrelevantOne successful trial proves the whole peptide family

5. Why does The Pep Report avoid generic click calculations for approved semaglutide pens?

Manufacturer-designed devices have product-specific instructions and should not be treated like generic research pensSemaglutide has no human evidenceAll pens use the same click scaleThe molecule cannot be delivered by injection

PThe Pep Report

Educational information only. Not medical advice.

Personalised Guide Safety & info Research Sourcing Guide